Sign In
Buy NTLA
$14.75
+1.73 (+13.29%)
At Close: Jun 04, 2026
Intellia (NTLA) Up on Positive Data Updates From HAE Study
11:43am, Monday, 12'th Jun 2023
Intellia's (NTLA) promising interim data on the early-stage study of NTLA-2002 shows potential as a single-dose treatment for hereditary angioedema.
Why Is Intellia (NTLA) Stock Up 5% Today?
10:07am, Monday, 12'th Jun 2023
Intellia (NASDAQ: NTLA ) is trending on social media, and NTLA stock is up over 5% today after the drugmaker reported new, positive results from one of its gene-edited treatments for hereditary angioe
Can This Gene-Editing Stock Deliver 10X Returns?
11:30am, Thursday, 08'th Jun 2023
Gene-editing stocks have sunk under the weight of rising interest rates and high inflation. These macroeconomic headwinds, however, may be creating a once-in-a-lifetime buying opportunity.
Wall Street Says These 2 Stocks May Double. Should You Buy Them?
02:00pm, Monday, 05'th Jun 2023
Intellia is advancing gene-editing candidates for diseases with limited treatment options. Invitae is making progress on a plan to speed up the timeline to positive cash flow.
CAMBRIDGE, Mass., May 31, 2023 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapies lever
Cathie Wood Is Loading Up on These 3 Stocks Down 70% or More. Should You?
05:50am, Tuesday, 16'th May 2023
Cathie Wood's Ark Invest ETFs added to their positions recently in two biotech stocks and one telehealth stock. All three stocks have plunged over the past couple of years.
Are You Looking for a Top Momentum Pick? Why Intellia Therapeutics, Inc. (NTLA) is a Great Choice
01:45pm, Tuesday, 09'th May 2023
Does Intellia Therapeutics, Inc. (NTLA) have what it takes to be a top stock pick for momentum investors? Let's find out.
Wall Street Analysts Think Intellia Therapeutics, Inc. (NTLA) Could Surge 115.12%: Read This Before Placing a Bet
11:28am, Tuesday, 09'th May 2023
The consensus price target hints at an 115.1% upside potential for Intellia Therapeutics, Inc. (NTLA). While empirical research shows that this sought-after metric is hardly effective, an upward trend
Intellia (NTLA) Beats on Q1 Earnings, Gives Pipeline Update
10:40am, Friday, 05'th May 2023
Intellia's (NTLA) first-quarter earnings beat estimates. The company provides updates on its gene-editing pipeline.
Intellia Therapeutics, Inc. (NTLA) Q1 2023 Earnings Call Transcript
12:08pm, Thursday, 04'th May 2023
Intellia Therapeutics, Inc. (NASDAQ:NTLA ) Q1 2023 Earnings Conference Call May 4, 2023 8:00 AM ET Company Participants Ian Karp - Senior Vice President, Investor Relations and Corporate Communication
The 3 Most Promising Gene Editing Stocks to Buy in 2023
04:51pm, Friday, 28'th Apr 2023
Gene editing stocks are one of the hottest sectors in medicine today. Genes are the foundation of life, and from creating new organisms to curing incurable diseases, the editing of genes can bring rad
Intellia Therapeutics to Hold Conference Call to Discuss First Quarter 2023 Earnings and Company Updates
07:30am, Thursday, 27'th Apr 2023
CAMBRIDGE, Mass., April 27, 2023 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapeutics
Intellia Therapeutics: Signs Of Possible Life
01:45pm, Friday, 21'st Apr 2023
Intellia Therapeutics: Signs Of Possible Life.
3 High-Growth Biotech Stocks Poised for Success in 2023
06:40am, Tuesday, 18'th Apr 2023
Many investors look for growth opportunities wherever they can find them. If that describes you, then there are some high-growth biotech stocks that could present an opportunity.
2 Monster Growth Stocks That Can Double in Value, According to Wall Street
05:19am, Friday, 14'th Apr 2023
Intellia Therapeutics is a gene-editing company with lots of potential if it can get an approved treatment or therapy. Rivian Automotive plans to double its production in 2023 as its business generate
